fluarix tetra
glaxo smith kline (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen - fluarix tetra is indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine.
betnovate scalp application
glaxo smith kline (israel) ltd - betamethasone as valerate - solution - betamethasone as valerate 0.1 %w/w - betamethasone - betamethasone - steroid responsive dermatoses of the scalp, such as psoriasis, seborrheic capitis and inflammation associated with severe dandruff.
ventolin syrup
glaxo smith kline (israel) ltd - salbutamol as sulfate - syrup - salbutamol as sulfate 2 mg / 5 ml - salbutamol - salbutamol - relief of bronchospasm in bronchial asthma of all types,chronic bronchitis,efmphysema.
ventolin tablets 2 mg
glaxo smith kline (israel) ltd - salbutamol as sulfate - tablets - salbutamol as sulfate 2 mg - salbutamol - salbutamol - relief of bronchospasm in bronchial asthma of all types, chronic bronchitis, emphysema.
duodart
glaxo smith kline (israel) ltd - dutasteride; tamsulosin hydrochloride - capsules - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin - tamsulosin - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph). reduction in the risk of acute urinary retention (aur) and surgery in patients with moderate to severe symptoms of bph.
duodart
glaxo smith kline (israel) ltd - dutasteride; tamsulosin hydrochloride - capsules - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph). reduction in the risk of acute urinary retention (aur) and surgery in patients with moderate to severe symptoms of bph.
duodart
glaxo smith kline (israel) ltd - dutasteride; tamsulosin hydrochloride - capsules - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph). reduction in the risk of acute urinary retention (aur) and surgery in patients with moderate to severe symptoms of bph.
duodart
glaxo smith kline (israel) ltd - dutasteride; tamsulosin hydrochloride - capsules - dutasteride 0.5 mg; tamsulosin hydrochloride 0.4 mg - tamsulosin - treatment of moderate to severe symptoms of benign prostatic hyperplasia (bph). reduction in the risk of acute urinary retention (aur) and surgery in patients with moderate to severe symptoms of bph.
nucala solution for injection
glaxo smith kline (israel) ltd - mepolizumab - solution for injection - mepolizumab 100 mg / 1 ml - mepolizumab - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patientschronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with corticosteroids and surgery in the last 10 years do not provide adequate disease control.eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (egpa).hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.
flolan infusion of epoprostenol 1500 mcg
glaxo smith kline (israel) ltd - epoprostenol as sodium - powder for solution for infusion - epoprostenol as sodium 1.5 mg/vial - epoprostenol - epoprostenol - flolan is indicated for the treatment of pulmonary arterial hypertension (pah) (idiopathic or heritable pah and pah associated with connective tissue diseases) in patients with who functional class iii-iv symptoms to improve exercise capacity